Sabra Health Care REIT Analyst Ratings
Sabra Health Care REIT Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 09/20/2023 | 12.28% | Jefferies | $11 → $15 | Upgrades | Hold → Buy |
| 08/11/2023 | 4.79% | B of A Securities | $11 → $14 | Upgrades | Underperform → Neutral |
| 07/27/2023 | -2.69% | Berenberg | → $13 | Initiates Coverage On | → Hold |
| 07/14/2023 | -6.44% | Citigroup | $11 → $12.5 | Maintains | Neutral |
| 04/25/2023 | -2.69% | Barclays | $15 → $13 | Maintains | Equal-Weight |
| 04/20/2023 | -17.66% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/19/2023 | -17.66% | Wells Fargo | → $11 | Initiates Coverage On | → Underweight |
| 04/12/2023 | -2.69% | Credit Suisse | → $13 | Reiterates | → Neutral |
| 03/29/2023 | -2.69% | Truist Securities | $14 → $13 | Maintains | Buy |
| 03/28/2023 | -21.41% | Citigroup | $13 → $10.5 | Maintains | Neutral |
| 12/13/2022 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 11/14/2022 | -2.69% | B of A Securities | $15 → $13 | Downgrades | Neutral → Underperform |
| 10/10/2022 | -2.69% | Baird | → $13 | Downgrades | Outperform → Neutral |
| 06/30/2022 | 4.79% | Jefferies | $15 → $14 | Downgrades | Buy → Hold |
| 05/25/2022 | 12.28% | Mizuho | $16 → $15 | Upgrades | Neutral → Buy |
| 04/18/2022 | 4.79% | Barclays | $16 → $14 | Downgrades | Overweight → Equal-Weight |
| 04/04/2022 | 12.28% | Credit Suisse | $14 → $15 | Maintains | Neutral |
| 03/11/2022 | 12.28% | B of A Securities | → $15 | Upgrades | Underperform → Neutral |
| 02/23/2022 | 34.73% | Stifel | $21 → $18 | Maintains | Buy |
| 02/18/2022 | — | Keybanc | Initiates Coverage On | → Sector Weight | |
| 02/01/2022 | 4.79% | Credit Suisse | → $14 | Initiates Coverage On | → Neutral |
| 09/30/2021 | 34.73% | Truist Securities | → $18 | Upgrades | Hold → Buy |
| 09/13/2021 | 49.7% | JMP Securities | $24 → $20 | Maintains | Market Outperform |
| 05/21/2021 | 57.19% | BMO Capital | $20 → $21 | Upgrades | Market Perform → Outperform |
| 05/10/2021 | 57.19% | Stifel | $17 → $21 | Upgrades | Hold → Buy |
| 01/13/2021 | 49.7% | Jefferies | $17 → $20 | Upgrades | Hold → Buy |
| 01/08/2021 | 42.22% | BMO Capital | → $19 | Upgrades | Underperform → Market Perform |
| 12/03/2020 | 79.64% | JMP Securities | → $24 | Upgrades | Market Perform → Market Outperform |
| 09/02/2020 | 12.28% | Stifel | → $15 | Reinstates | → Hold |
| 06/23/2020 | 12.28% | Scotiabank | $12 → $15 | Upgrades | Sector Underperform → Sector Perform |
| 06/22/2020 | 4.79% | Wells Fargo | $13 → $14 | Maintains | Equal-Weight |
| 05/18/2020 | 12.28% | Berenberg | → $15 | Upgrades | Hold → Buy |
| 04/23/2020 | — | SunTrust Robinson Humphrey | Maintains | Hold | |
| 04/07/2020 | -25.15% | Citigroup | $20 → $10 | Maintains | Neutral |
| 03/26/2020 | -21.41% | Wells Fargo | $22 → $10.5 | Maintains | Equal-Weight |
| 02/26/2020 | 64.67% | Mizuho | → $22 | Upgrades | Neutral → Buy |
| 02/06/2020 | 87.13% | Barclays | $26 → $25 | Maintains | Overweight |
| 02/05/2020 | 64.67% | Berenberg | → $22 | Initiates Coverage On | → Hold |
| 12/20/2019 | 64.67% | Mizuho | → $22 | Initiates Coverage On | → Neutral |
| 12/18/2019 | — | Citigroup | Upgrades | Sell → Neutral | |
| 10/14/2019 | — | B of A Securities | Reinstates | → Neutral | |
| 09/27/2019 | 72.16% | JMP Securities | $22 → $23 | Maintains | Market Outperform |
| 09/23/2019 | 49.7% | Citigroup | $18 → $20 | Downgrades | Neutral → Sell |
| 09/03/2019 | 79.64% | Barclays | → $24 | Initiates Coverage On | → Overweight |
| 02/26/2019 | — | BMO Capital | Downgrades | Market Perform → Underperform | |
| 12/17/2018 | 42.22% | Wells Fargo | $23 → $19 | Maintains | Market Perform |
| 11/16/2018 | 57.19% | B of A Securities | $23 → $21 | Downgrades | Neutral → Underperform |
| 11/16/2018 | — | Raymond James | Downgrades | Outperform → Market Perform | |
| 11/13/2018 | 57.19% | Mizuho | → $21 | Downgrades | Buy → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 09/20/2023 | 12.28% | 杰富瑞 | $11→$15 | 升级 | 持有→购买 |
| 2023年08月11日 | 4.79% | B of A证券 | $11→$14 | 升级 | 表现不佳的→中性 |
| 07/27/2023 | -2.69% | 贝伦伯格 | →$13 | 开始承保 | →保留 |
| 07/14/2023 | -6.44% | 花旗集团 | $11→$12.5 | 维护 | 中性 |
| 04/25/2023 | -2.69% | 巴克莱 | $15→$13 | 维护 | 等重 |
| 04/20/2023 | -17.66% | 富国银行 | →$11 | 开始承保 | →减持 |
| 04/19/2023 | -17.66% | 富国银行 | →$11 | 开始承保 | →减持 |
| 04/12/2023 | -2.69% | 瑞士信贷 | →$13 | 重申 | →中性 |
| 03/29/2023 | -2.69% | Truist证券 | $14→$13 | 维护 | 买 |
| 03/28/2023 | -21.41% | 花旗集团 | $13→$10.5 | 维护 | 中性 |
| 2022年12月13日 | - | JMP证券 | 评级下调 | 市场表现优于→市场表现 | |
| 2022年11月14日 | -2.69% | B of A证券 | $15→$13 | 评级下调 | 中性→表现不佳 |
| 2022年10月10日 | -2.69% | 贝尔德 | →$13 | 评级下调 | 跑赢→中性 |
| 2022/06/30 | 4.79% | 杰富瑞 | $15→$14 | 评级下调 | 购买→Hold |
| 2022年05月25日 | 12.28% | 瑞穗 | $16→$15 | 升级 | 中性→购买 |
| 04/18/2022 | 4.79% | 巴克莱 | $16→$14 | 评级下调 | 超重→等重 |
| 04/04/2022 | 12.28% | 瑞士信贷 | $14→$15 | 维护 | 中性 |
| 03/11/2022 | 12.28% | B of A证券 | →$15 | 升级 | 表现不佳的→中性 |
| 02/23/2022 | 34.73% | Stifel | $21→$18 | 维护 | 买 |
| 02/18/2022 | - | KeyBanc | 开始承保 | →行业权重 | |
| 02/01/2022 | 4.79% | 瑞士信贷 | →$14 | 开始承保 | →中性 |
| 09/30/2021 | 34.73% | Truist证券 | →$18 | 升级 | 持有→购买 |
| 09/13/2021 | 49.7% | JMP证券 | $24→$20 | 维护 | 市场表现强于大盘 |
| 2021/05/21 | 57.19% | 蒙特利尔银行资本 | $20→$21 | 升级 | 市场表现优于→ |
| 2021/05/10 | 57.19% | Stifel | $17→$21 | 升级 | 持有→购买 |
| 2021/01/13 | 49.7% | 杰富瑞 | $17→$20 | 升级 | 持有→购买 |
| 01/08/2021 | 42.22% | 蒙特利尔银行资本 | →$19 | 升级 | 表现逊于→市场表现 |
| 12/03/2020 | 79.64% | JMP证券 | →$24 | 升级 | 市场表现优于→市场表现 |
| 09/02/2020 | 12.28% | Stifel | →$15 | 恢复 | →保留 |
| 2020/06/23 | 12.28% | 加拿大丰业银行 | $12→$15 | 升级 | 行业表现逊于→行业表现 |
| 06/22/2020 | 4.79% | 富国银行 | $13→$14 | 维护 | 等重 |
| 05/18/2020 | 12.28% | 贝伦伯格 | →$15 | 升级 | 持有→购买 |
| 04/23/2020 | - | SunTrust Robinson Humphrey | 维护 | 保持 | |
| 04/07/2020 | -25.15% | 花旗集团 | $20→$10 | 维护 | 中性 |
| 03/26/2020 | -21.41% | 富国银行 | $22→$10.5 | 维护 | 等重 |
| 02/26/2020 | 64.67% | 瑞穗 | →$22 | 升级 | 中性→购买 |
| 02/06/2020 | 87.13% | 巴克莱 | $26→$25 | 维护 | 超重 |
| 02/05/2020 | 64.67% | 贝伦伯格 | →$22 | 开始承保 | →保留 |
| 2019年12月20日 | 64.67% | 瑞穗 | →$22 | 开始承保 | →中性 |
| 2019年12月18日 | - | 花旗集团 | 升级 | 卖出→中性 | |
| 2019年10月14日 | - | B of A证券 | 恢复 | →中性 | |
| 2019年09月27日 | 72.16% | JMP证券 | $22→$23 | 维护 | 市场表现强于大盘 |
| 2019年09月23日 | 49.7% | 花旗集团 | $18→$20 | 评级下调 | 中性→销售 |
| 2019年09月03日 | 79.64% | 巴克莱 | →$24 | 开始承保 | →超重 |
| 2019年02月26日 | - | 蒙特利尔银行资本 | 评级下调 | 市场表现→表现不佳 | |
| 2018年12月17日 | 42.22% | 富国银行 | $23→$19 | 维护 | 市场表现 |
| 2018年11月16日 | 57.19% | B of A证券 | $23→$21 | 评级下调 | 中性→表现不佳 |
| 2018年11月16日 | - | 雷蒙德·詹姆斯 | 评级下调 | 跑赢→市场表现 | |
| 2018年11月13日 | 57.19% | 瑞穗 | →$21 | 评级下调 | 购买→中性 |
What is the target price for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的目标价格是多少？
The latest price target for Sabra Health Care REIT (NASDAQ: SBRA) was reported by Jefferies on September 20, 2023. The analyst firm set a price target for $15.00 expecting SBRA to rise to within 12 months (a possible 12.28% upside). 13 analyst firms have reported ratings in the last year.
杰富瑞于2023年9月20日报道了Sabra Health Care REIT(纳斯达克：SBRA)的最新目标价。这家分析公司将目标价定为15.00美元，预计SBRA将在12个月内上涨(可能上涨12.28%)。过去一年，有13家分析公司公布了评级。
What is the most recent analyst rating for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的最新分析师评级是多少？
The latest analyst rating for Sabra Health Care REIT (NASDAQ: SBRA) was provided by Jefferies, and Sabra Health Care REIT upgraded their buy rating.
杰富瑞给予Sabra Health Care REIT(纳斯达克代码：SBRA)的最新分析师评级，Sabra Health Care REIT上调其买入评级。
When is the next analyst rating going to be posted or updated for Sabra Health Care REIT (SBRA)?
Sabra Health Care REIT(SBRA)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sabra Health Care REIT, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sabra Health Care REIT was filed on September 20, 2023 so you should expect the next rating to be made available sometime around September 20, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Sabra Health Care REIT的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Sabra Health Care REIT的上一次评级是在2023年9月20日提交的，因此您应该预计下一次评级将在2024年9月20日左右的某个时候提供。
Is the Analyst Rating Sabra Health Care REIT (SBRA) correct?
分析师对Sabra Health Care REIT(SBRA)的评级正确吗？
While ratings are subjective and will change, the latest Sabra Health Care REIT (SBRA) rating was a upgraded with a price target of $11.00 to $15.00. The current price Sabra Health Care REIT (SBRA) is trading at is $13.36, which is within the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Sabra Health Care REIT(SBRA)评级被上调，目标价为11.00美元至15.00美元。Sabra Health Care REIT(SBRA)目前的交易价格为13.36美元，在分析师的预测范围内。